Cargando…
Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?
The mainstay of treatment for metastatic prostate cancer is androgen deprivation therapy (ADT). Outcomes with ADT are variable but control of hormone-sensitive prostate cancer (HSPC) can often be achieved for many years. Death from prostate cancer is usually due to the development of escape variants...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969504/ https://www.ncbi.nlm.nih.gov/pubmed/35371297 http://dx.doi.org/10.1177/17588359221086827 |